Treatment Options
249 articles
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
Phase II mRNA Vaccine Trial Opens
The mRNA vaccine phase II clinical trial, led by Dr. Vinod Balachandran, has opened at Memorial Sloan Kettering, with other locations soon to come.
Exercise Helps Boost Immune System and Immunotherapy Treatment
Dr. Emma Kurz is part of a research team that has found that exercise can help make immunotherapy more effective for pancreatic cancer.
Using A Virus to Reach the Tumor
Dr. Tara Seery is fascinated by the potential of an oncolytic virus to make chemotherapy more effective for pancreatic cancer.
The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day One
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
The First Line of Defense against Pancreatic Cancer
Drs. Allyson Ocean and David Tuveson explain why pancreatic cancer patients should participate in clinical trials at the time of diagnosis.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
What Happens When Pancreatic Cancer Clinical Trials Fail?
Why do clinical trials fail? What about the patients on the trial? Learn more about what happens when pancreatic cancer clinical trials fail.
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
Standard of Care Plus
Dr. Allyson Ocean explains why pancreatic cancer patients should consider clinical trials, which go beyond standard of care.
Drug Onivyde Gives New Hope to Patients with Advanced Pancreatic Cancer
Onivyde (injectable irinotecan), combined with fluorouracil and leucovorin, has been approved as a second-line treatment for advanced pancreatic cancer.
Large Clinical Trial For Cachexia Treatment
Lead investigator Dr. Jeffrey Crawford reports on the positive results from a cachexia clinical trial of a new immunotherapy drug to treat the condition.
A Look at MEK and Autophagy Inhibition
Dr. Conan Kinsey looks at the MEK pathway as way to make immunotherapy more effective for pancreatic cancer patients.
New Study Combines Checkpoint Inhibitors with Radiation Therapy to Boost Immune Response
Dr. Theodore Hong combines checkpoint inhibitors–a type of immunotherapy–with radiation to boost the immune system in pancreatic cancer treatment.